Exelixis (EXEL) : Traders are bullish on Exelixis (EXEL) as it has outperformed the S&P 500 by a wide margin of 6.4% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 2.03%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 3.56% in the last 1 week, and is up 11.05% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 6.97% and the 50-Day Moving Average is 24.05%.
Exelixis (NASDAQ:EXEL): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $8.29 and $8.19 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $8.48. The buying momentum continued till the end and the stock did not give up its gains. It closed at $8.44, notching a gain of 2.68% for the day. The total traded volume was 6,089,624 . The stock had closed at $8.22 on the previous day.
The company Insiders own 5.9% of Exelixis shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 11.81% . Institutional Investors own 77.15% of Exelixis shares. During last six month period, the net percent change held by insiders has seen a change of 11.81%. In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Exelixis, Inc., Willsey Lance, had purchased 60,000 shares in a transaction dated on May 9, 2016. The transaction was executed at $4.96 per share with total amount equaling $297,600.
Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Companys other programs include metastatic renal cell carcinoma (mRCC), a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL, a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888, a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).